ALLO
Allogene TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
The strongest positive read-through is that Allogene now has more time to fund its key programs, while the stored Q1 earnings context points to directionally constructive ALPHA3 interim futility data and early ALLO-329 observations. If ALLO-329 continues to show tolerability and activity into the Q4 2026 update, investors could start to underwrite more than a one-asset story, but the evidence remains early [#SEC-8K-2026-05-13][#PR-EARNINGS-2026-05-14].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Clinical-risk concentration is high: the next meaningful upside case still depends on ALLO-329 and the longer-dated ALPHA3 EFS readout rather than current operating fundamentals [#SEC-8K-2026-05-13][#PR-EARNINGS-2026-05-14].
Momentum
96
Value
41
Sentiment
56
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.90 · Bull $3.50 · Bear $0.80
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-11 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $8.49
Why
Momentum96 · Δ7d -
Value41 · Δ7d -0.1
Sentiment56 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
96
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
56
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 96.4 / Value 41.1 / Sentiment 55.9
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$617.83M
Beta
0.60
Shares Out
345.16M
P/E (TTM) · Derived
-2.1
P/S (TTM)
-
P/FCF (TTM) · Derived
-3.66
Rev YoY
-100.0%
EPS YoY
-36.1%
Gross Margin
-61895.5%
Op Margin
-1241814.0%
Net Debt
-$166.96M
Current Ratio
9.65
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology